A Prospective, Multicenter, Single-arm, Open-label, Interventional Phase IV Study to Evaluate the Safety and Efficacy of Idursulfase (r-DNA Origin) (Elaprase™) in Indian Pediatric and Adult Population With Hunter Syndrome (Mucopolysaccharidosis II)
Latest Information Update: 24 Jul 2023
At a glance
- Drugs Idursulfase (Primary)
- Indications Mucopolysaccharidosis II
- Focus Adverse reactions
- Sponsors Shire
- 18 Jul 2023 Planned End Date changed from 30 Apr 2024 to 30 Sep 2024.
- 18 Jul 2023 Planned primary completion date changed from 30 Mar 2024 to 31 Aug 2024.
- 05 May 2022 Status changed from not yet recruiting to recruiting.